CatalentCTLT
Market Cap: $10.9B
About: Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Employees: 17,219
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
22% more funds holding in top 10
Funds holding in top 10: 9 [Q1] → 11 (+2) [Q2]
14% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 59
2% more funds holding
Funds holding: 425 [Q1] → 433 (+8) [Q2]
6% less capital invested
Capital invested by funds: $9.91B [Q1] → $9.33B (-$573M) [Q2]
14% less repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 166
30% less call options, than puts
Call options by funds: $36.2M | Put options by funds: $51.9M
49.06% less ownership
Funds ownership: 140.78% [Q1] → 91.73% (-49.06%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
RBC Capital Sean Dodge 55% 1-year accuracy 24 / 44 met price target | 6%upside $64 | Sector Perform Reiterated | 11 Jul 2024 |
Barclays Luke Sergott 60% 1-year accuracy 28 / 47 met price target | 5%upside $63 | Equal-Weight Maintained | 28 Jun 2024 |
Financial journalist opinion
Based on 5 articles about CTLT published over the past 30 days